Cargando…
Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?
Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protec...
Autor principal: | Delma, Mohamed Islam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657315/ https://www.ncbi.nlm.nih.gov/pubmed/33194476 http://dx.doi.org/10.7759/cureus.10909 |
Ejemplares similares
-
Thrombosis – Besieged but Poorly Understood
por: Lang, Irene M.
Publicado: (2014) -
Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale
por: Arivazhagan, Sowbharnika, et al.
Publicado: (2021) -
A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy
por: Cox, Ronald E, et al.
Publicado: (2021) -
A Unicorn Disease: The Large Duct Variant of Invasive Ductal Adenocarcinoma of the Pancreas
por: Elhariri, Ahmed, et al.
Publicado: (2023) -
Healthcare under siege: a qualitative study of health-worker responses to targeting and besiegement in Syria
por: Fardousi, Nasser, et al.
Publicado: (2019)